FTY720的潜在能力:针对疾病的新型治疗功能,点和机制
1Center of Clinical Laboratory and Translational Medicine, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Suzhou, Jiangsu, PR China.
European journal of medicinal chemistry
|March 22, 2025
概括
芬戈利莫德 (FTY720),一种S1P受体调节剂,已被批准用于多发性硬化症. 新兴研究揭示了它在MS以外的各种疾病中的潜力,包括癌症和神经系统疾病.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 神经学 神经学
背景情况:
- 芬戈利莫德 (FTY720) 是FDA批准的用于治疗多发性硬化症 (MS) 的斯芬戈-1-酸盐 (S1P) 受体调节剂.
- 它的非选择性S1P受体激动作用影响多个系统,推动了对新型应用的广泛研究.
- FTY720的系统性作用和多种受体相互作用需要全面了解其治疗潜力.
研究的目的:
- 审查FTY720的新角色,目标和机制,超出其在MS的既定用途.
- 探索FTY720在器官移植,免疫疾病,瘤学和神经疾病方面的潜力.
- 总结FTY720的发展,结构与活动的关系,安全以及未来的研究方向.
主要方法:
- 关于FTY720功能和应用的最新研究的文献综述.
- 分析FTY720的作用机制,包括它与S1P受体 (S1PRs) 的结合.
- 检查FTY720对血脑屏障,血管系统,器官和细胞死亡的影响.
主要成果:
- FTY720在各种疾病中表现出潜在的治疗作用,包括器官移植,免疫系统疾病,瘤,神经和精神疾病.
- 发现的新功能包括调节血脑屏障,血管系统和细胞死亡途径.
- 这篇论文详细介绍了FTY720的衍生,发展以及其与S1PRs相互作用的结构基础.
结论:
- 在多发性硬化症以外的临床应用中,FTY720具有显著的前景.
- 需要进一步的研究,以充分阐明其机制,并优化其治疗用途.
- 应对挑战和开发战略方法将最大限度地发挥FTY720的临床潜力.
更多相关视频
07:32Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
7.6K
10:21Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
Published on: February 23, 2024
2.3K
相关概念视频
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
01:26Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:24Principles of Drug Action
5.7K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
5.7K